A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Lymphoma
DRUG: TLN-254|DRUG: TLN-254
Percentage of Participants With Objective Response, Up to 2 years|Percentage of Participants With CR, Up to 2 years|Percentage of Participants With PR, Up to 2 years
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Up to 2 years|Number of Participants With Severity of TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0, Up to 2 years|Plasma concentrations of TLN-254, Day 1 of Cycle 1 and Day 1 of each even numbered Cycle for up to 2 years (Each Cycle length =28 days)|Duration of Response (DOR), Up to 2 years
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.